NorthStar Medical Radioisotopes has expanded its strategic collaboration with Convergent Therapeutics, the company announced recently.

According to a release, NorthStar will:

• Provide Convergent with Ac-225 for use in CONVO1-a,
• Use its new contract development and manufacturing facility to manufacture CONVO1-a to serve patients in Convergent’s clinical trials, and
• Perform research and development activities to support the continued development of CONVO1-a and other Convergent assets.

“At NorthStar, our passion is to reduce technological and operational barriers to help companies like Convergent Therapeutics not only secure a reliable source of Ac-225, but manufacture a finished, patient-ready drug product and continue to develop new and additional therapeutic indications for the patients who need new and better medicines,” NorthStar CEO Frank Scholz said in a statement. “We are proud to be supporting Convergent and look forward to working with them to help make new medicines like CONV01-α therapeutic reality.”

The manufacturing supply agreement will support Convergent’s Phase 2 studies, and if the U.S. Food and Drug Administration (FDA) approves, the manufacturing of CONVO1-a for commercial use.